# Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers

> **NCT01031199** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Positron-Emission Tomography
- Multiple Sclerosis

## Interventions

- **DRUG:** F-18 FEDAA1106 (BAY85-8101)
- **DRUG:** F-18 FEDAA1106 (BAY85-8101)

## Key facts

- **NCT ID:** NCT01031199
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031199, "Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01031199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*